{"id":"NCT02505334","sponsor":"Novo Nordisk A/S","briefTitle":"A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.","officialTitle":"A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-21","primaryCompletion":"2017-05-02","completion":"2017-11-09","firstPosted":"2015-07-22","resultsPosted":"2018-06-25","lastUpdate":"2018-09-05"},"enrollment":635,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"liraglutide","otherNames":[]}],"arms":[{"label":"Liraglutide 1.8 mg","type":"EXPERIMENTAL"},{"label":"Liraglutide 0.9 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in Asia. The aim of the trial is to compare the efficacy and safety of liraglutide 1.8 mg/day to liraglutide 0.9 mg/day in Japanese subjects with type 2 diabetes mellitus.","primaryOutcome":{"measure":"Change in Glycosylated Haemoglobin (HbA1c) (Week 26)","timeFrame":"Week 0, Week 26","effectByArm":[{"arm":"Liraglutide 1.8 mg","deltaMin":-0.23,"sd":0.06},{"arm":"Liraglutide 0.9 mg","deltaMin":0.17,"sd":0.06}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":47,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":233},"commonTop":["Viral upper respiratory tract infection","Diabetic retinopathy","Constipation","Lipase increased"]}}